Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.

[1]  M. Kudo,et al.  Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240 , 2020, Cancer.

[2]  M. Kudo,et al.  O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150 , 2020 .

[3]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[4]  M. Kudo,et al.  Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2 , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[5]  M. Kudo,et al.  CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). , 2020 .

[6]  Michael Koller,et al.  International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. , 2020, The Lancet. Oncology.

[7]  J. Foucaud,et al.  Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials , 2020, PloS one.

[8]  J. Reijneveld,et al.  Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. , 2019, The Lancet. Oncology.

[9]  P. Rutkowski,et al.  Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors , 2019, Postepy dermatologii i alergologii.

[10]  Sunil Sharma,et al.  Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life , 2019, Cancers.

[11]  J. Roydhouse,et al.  Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials. , 2019, JAMA oncology.

[12]  L. Howie,et al.  Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions , 2019, Clinical trials.

[13]  N. Freemantle,et al.  Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial. , 2019, Journal of Clinical Oncology.

[14]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[15]  L. Minasian,et al.  Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections , 2017, Clinical Cancer Research.

[16]  M. Kudo,et al.  618OHealth-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR) , 2017 .

[17]  E. Basch,et al.  Trustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials. , 2017, JAMA oncology.

[18]  W. Yeo,et al.  Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data , 2017, BMC Cancer.

[19]  M. Kudo,et al.  Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial , 2016 .

[20]  I. Tannock,et al.  Under-reporting of harm in clinical trials. , 2016, The Lancet. Oncology.

[21]  X. Paoletti,et al.  The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. , 2013, Journal of hepatology.

[22]  David Moher,et al.  Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. , 2013, JAMA.

[23]  P. Fayers,et al.  Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2012, European journal of cancer.

[24]  L. Trinquart,et al.  International cross‐cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality‐of‐life questionnaire HCC18 , 2012, Hepatology.

[25]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[26]  W. Chie,et al.  Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. , 2004, European journal of cancer.

[27]  H. Friess,et al.  Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. , 1999, European journal of cancer.

[28]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.